메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease

SHANGHAI and HANGZHOU, China, Dec. 15, 2025 -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application to initiate global Phase Ⅲ clinical trials of MHB018A for the treatment of thyroid eye disease (TED). The trials in both active and chronic TED are randomized, double-blind, placebo-controlled studies designed to evaluate the efficacy and safety of subcutaneous MHB018A administered every four
- 김갑성 기자
- 2025-12-15 18:00
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor

- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing. - ASC50 had strong target engagement after a single oral dose, indicated by elevated plasma interleukin-17A (IL-17A) levels, which continued until day 7 for higher doses of ASC50. - ASC50 demonstrated a dose-proportional pharmacokinetic profile from 10 mg to 600 mg in single ascending dose study in healthy participants. - ASC50 was safe and we
- 김갑성 기자
- 2025-12-15 17:00
MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine

[ 메디채널 김갑성 기자 ] The company is revolutionizing regenerative healthcare through innovation, clinical alignment, and GMP-grade excellence across Southeast Asia SAN ANTONIO, Dec. 15, 2025 -- Frost & Sullivan is pleased to announce that MEDEZE Group Public Company Limited (MEDEZE) has been honored with the 2025 Southeast Asia Company of the Year Recognition in the stem cell banking and regenerative medicine industry for its outstanding achievements in innovation, regulatory leadership, and clinical alignment. This recognition highlights MEDEZE's leadership in advancing the next gener
- 김갑성 기자
- 2025-12-15 17:00
Global Spotlight｜POGMENT Biomimetic Collagen "Stable Triple Helix" Breakthrough Stuns the World--Extraordinary and Breathtaking

CHENGDU, China, Dec. 15, 2025 -- Recently, LivingPhoenix Regenerative Technologies has captured widespread attention with its world-first "Stable Triple-Helix Biomimetic Collagen" technology, making consecutive appearances at 12 high-level academic conferences in November. These events spanned aesthetic medicine, regenerative medicine, and personal care. Several academicians and industry experts have unanimously hailed the innovation as a mark of collagen R&D's evolution from "animal extraction" and "genetic recombination" to "structural design." Re
- 김갑성 기자
- 2025-12-15 16:32
Medit Announces 2025 Year-End Promotion

SEOUL, South Korea, Dec. 15, 2025 -- Medit, a global leader in 3D dental scanning solutions, announced the launch of "Medit's 2025 End of Year Promotion," a limited-time campaign delivering significant benefits to dental professionals worldwide. Dental professionals can learn more about the promotion details and encourage to leave their contact information at https://www.medit.com/medit-mobility-trade-up-promotion2025/. The promotion celebrates the debut of the Medit i900 Mobility, offering exclusive launch promotions alongside major upgrade opportunities across the Medit i9
- 김갑성 기자
- 2025-12-15 16:00
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT

[ 메디채널 김갑성 기자 ] Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressure medication over 2 years Of the 286 adult patients dosed in the trial, 69 have already completed the full 2-year treatment period and of those, 65 entered voluntarily into the Open Label Extension (OLE) study, representing 94% OLE uptake The study has now successfully passed seven sc
- 김갑성 기자
- 2025-12-15 15:02
LifeWave Highlights Five Key Focus Areas at Taiwan-Hong Kong-Macau Annual Conference, Featuring a Boundary-Breaking Indoor Drone Opening

TAIPEI, Dec. 15, 2025 -- LifeWave hosted the SHARE THE LIGHT Taiwan–Hong Kong–Macau Annual Recognition Conference on December 14 at the Taipei International Convention Center, bringing together nearly 2,000 Brand Partners and guests. The event marked a milestone, reflecting LifeWave's 17 years of growth and market development in Taiwan. The conference opened with an innovative drone light performance that brought large-scale drone formations—traditionally seen outdoors—onto an indoor stage. Through cross-venue technology integration, the performance demonstrated new possibiliti
- 노기식 기자
- 2025-12-15 14:12
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.

STOCKHOLM, Dec. 15, 2025 -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is expected to close in the first half of 2026. Viva Biotech expects that the
- 김갑성 기자
- 2025-12-15 14:06
Manulife and Bupa Sign MoU for Strategic Collaboration in Hong Kong to Create a More Robust, Integrated Healthcare Network Offering Customers Greater Access and Choice

HONG KONG, Dec. 15, 2025 -- Manulife (International) Limited ("Manulife") and Bupa International Limited ("Bupa") are pleased to announce today the signing of a Memorandum of Understanding ("MoU"), intended to establish a strategic collaboration in Hong Kong that will provide customers with greater convenience and flexibility in managing their health. United by a shared commitment to enhancing healthcare and wellbeing for the people of Hong Kong, this proposed strategic collaboration will combine the strengths of two industry leaders to build a more robust
- 황정호 기자
- 2025-12-15 13:45
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder

SHANGHAI, Dec. 15, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the launch of its 2030 Strategy, outlining a comprehensive five-year roadmap to drive sustainable growth. Under this strategy, the Company aims to further deepen its product pipeline, maximize the value of its commercial platform, and advance the globalization of its research and development ("R&D") and commercializa
- 김갑성 기자
- 2025-12-15 12:40

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-19_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 19일 05시 00분